focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBenchmark Holdings Regulatory News (BMK)

Share Price Information for Benchmark Holdings (BMK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 44.95
Bid: 44.00
Ask: 45.90
Change: 0.45 (1.01%)
Spread: 1.90 (4.318%)
Open: 44.50
High: 0.00
Low: 0.00
Prev. Close: 44.50
BMK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Acquisition of remaining minority interest

17 Feb 2023 07:00

RNS Number : 2196Q
Benchmark Holdings PLC
17 February 2023
 

RNS Reach

17 February 2023

Benchmark Holdings plc

("Benchmark", the Group, or the "Company")

Acquisition of remaining minority interest in Benchmark Genetics Iceland

Benchmark Holdings, the aquaculture biotechnology company, announces that it has acquired the remaining 10.52% minority interest in its subsidiary Benchmark Genetics Iceland. Enhanced by the recent construction of a new incubation centre, Benchmark Genetics Iceland is core to the Company's ability to supply highly specialist, biosecure salmon eggs to salmon producers to c.35 countries around the world, year-round. Benchmark Genetics Iceland represents 50% of the Group's salmon egg capacity.

Background

In December 2014 Benchmark acquired a 89.48% interest in Stofnfiskur, subsequently rebranding it Benchmark Genetics Iceland and merging it with its salmon genetics business in Norway. Since the acquisition, the business has grown substantially, benefitting from Benchmark's leading market position, investment and knowledge transfer within the Group. 

Trond Williksen commented:

"Benchmark's genetics operations in Iceland have a 200m egg capacity and are core to our ability to supply highly biosecure salmon eggs year round to customers around the world. The acquisition of the remaining minority interest is a natural step in delivering shareholder value through full ownership of the success of our genetics business."

Rabobank acted as financial adviser to Benchmark in the transaction.

Enquiries

For further information, please contact:

Benchmark Holdings plc

Tel: 020 3696 0630

Trond Williksen, CEO

Septima Maguire, CFO

Ivonne Cantu, Investor Relations

Numis (Broker and NOMAD)

Tel: 020 7260 1000

James Black, Freddie Barnfield, Duncan Monteith

 

MHP

Tel: 020 3128 8004

Katie Hunt, Reg Hoare, Veronica Farah

benchmark@mhpgroup.com

 

About Benchmark 

Benchmark is a market leading aquaculture biotechnology company. Benchmark's mission is to drive sustainability in aquaculture by delivering products and solutions in genetics, advanced nutrition and health which improve yield, growth and animal health and welfare.

Through a global footprint in 26 countries and a broad portfolio of products and solutions, Benchmark serves major aquaculture species - salmon, shrimp, sea bass and bream and tilapia - in main aquaculture regions around the world. Find out more at www.benchmarkplc.com

 

 

 

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NRATFMBTMTBBTRJ
Date   Source Headline
11th Sep 20205:58 pmRNSHolding(s) in Company
10th Sep 20209:15 amRNSPositive Opinion from the EMA on BMK08
4th Sep 20207:00 amRNSDirector/PDMR Shareholding
28th Aug 20207:00 amRNSTotal Voting Rights
28th Aug 20207:00 amRNSQ3 Results
21st Aug 20207:00 amRNSNotice of Q3 Results
31st Jul 202011:17 amRNSCompletion of sale of vaccine facility
31st Jul 20207:00 amRNSTotal Voting Rights
23rd Jul 202011:05 amRNSSale of vaccine manufacturing assets
1st Jul 20207:00 amRNSSale of FishVet
30th Jun 20207:00 amRNSTotal Voting Rights
23rd Jun 20207:00 amRNSSale of Improve International
8th Jun 20204:54 pmRNSDirector/PDMR Shareholding - Replacement
8th Jun 202010:43 amRNSDirector/PDMR Shareholding
5th Jun 20205:50 pmRNSDirector/PDMR Shareholding
29th May 20207:00 amRNSTotal Voting Rights
29th May 20207:00 amRNSSecond Quarter and Interim Results
27th May 20208:30 amRNSEquity Development Results Webinar
19th May 20207:00 amRNSNotice of Q2 and Interim Results
6th May 202012:09 pmRNSHolding(s) in Company
30th Apr 20207:00 amRNSTotal Voting Rights
21st Apr 20207:00 amRNSDirector and Divisional Management Changes
7th Apr 20207:00 amRNSAppointment of Chief Executive Officer
2nd Apr 20207:00 amRNSCovid-19 update
31st Mar 202011:12 amRNSTotal Voting Rights
20th Mar 20207:00 amRNSBlock Listing Six Monthly Review
18th Mar 20207:00 amRNSBlock Admission Application
16th Mar 202012:00 pmRNSDirector Dealings
12th Mar 20201:15 pmRNSResult of AGM
9th Mar 20202:01 pmRNSHolding(s) in Company
9th Mar 20201:46 pmRNSDIRECTOR DEALINGS
28th Feb 20207:00 amRNSTotal Voting Rights
28th Feb 20207:00 amRNSQ1 Results
25th Feb 20209:43 amRNSDIRECTOR SHARE OPTIONS
21st Feb 202010:49 amRNSDirector/PDMR Shareholding
20th Feb 20204:10 pmRNSHolding(s) in Company
20th Feb 20209:15 amRNSHolding(s) in Company
17th Feb 20204:28 pmRNSResult of General Meeting and Total Voting Rights
17th Feb 20207:00 amRNSResult of Open Offer
11th Feb 20207:00 amRNSPosting of Annual Report & Accounts &Notice of AGM
31st Jan 20207:00 amRNSTotal Voting Rights
30th Jan 20202:46 pmRNSTimetable for Placing and Open Offer
30th Jan 20207:00 amRNSPlacing and Open Offer
31st Dec 20197:00 amRNSTotal Voting Rights
20th Dec 20199:06 amRNSSecond Price Monitoring Extn
20th Dec 20199:00 amRNSPrice Monitoring Extension
20th Dec 20197:00 amRNSQ4 Results
20th Dec 20197:00 amRNSFull Year Results
4th Dec 20197:00 amRNSDirectorate Change
29th Nov 20197:00 amRNSQ4 and FY Trading Update & Notice of Results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.